Aubagio and Hair loss - a phase IV clinical study of FDA data
Summary:
Hair loss is found among people who take Aubagio, especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months.
The phase IV clinical study analyzes which people take Aubagio and have Hair loss. It is created by eHealthMe based on reports of 43,868 people who have side effects when taking Aubagio from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
43,868 people reported to have side effects when taking Aubagio.
Among them, 6,663 people (15.19%) have Hair loss.
What is Aubagio?
Aubagio has active ingredients of teriflunomide. It is often used in multiple sclerosis. eHealthMe is studying from 44,011 Aubagio users for its effectiveness, alternative drugs and more.
What is Hair loss?
Hair loss is found to be associated with 3,775 drugs and 3,314 conditions by eHealthMe.
Number of Aubagio and Hair loss reports submitted per year:
Time on Aubagio when people have Hair loss *:
Gender of people who have Hair loss when taking Aubagio*:
Age of people who have Hair loss when taking Aubagio *:
Common drugs people take besides Aubagio *:
Common side effects people have besides Hair loss *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Aubagio and have Hair loss?
Check whether Hair loss is associated with a drug or a conditionHow to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Lindsey SF, Tosti A, "Hair loss induced by tumor necrosis factor alpha inhibitors", J Clin Investigat Dermatol, 2015 Jan .
Related studies
How severe was Hair loss and when was it recovered:
Expand to all the drugs that have ingredients of teriflunomide:
- Hair loss and drugs with ingredients of teriflunomide (6,406 reports)
Alternative drugs to, pros and cons of Aubagio:
- Aubagio (44,011 reports)
Common Aubagio side effects:
- Hair loss: 6,663 reports
- Fatigue (feeling of tiredness): 5,357 reports
- Diarrhea: 5,234 reports
- Headache (pain in head): 3,157 reports
- Weakness: 3,123 reports
Browse all side effects of Aubagio:
a b c d e f g h i j k l m n o p q r s t u v w x y zHair loss treatments and more:
- Hair loss (238,525 reports)
COVID vaccines that are related to Hair loss:
- Hair loss in Moderna COVID Vaccine
- Hair loss in Pfizer BioNTech Covid Vaccine
- Hair loss in Johnson and Johnson Covid Vaccine
Common drugs associated with Hair loss:
- Taxotere: 34,064 reports
- Docetaxel: 25,062 reports
- Methotrexate: 16,710 reports
- Humira: 14,833 reports
- Enbrel: 14,300 reports
- Prednisone: 13,908 reports
- Neosar: 11,976 reports
- Remicade: 10,226 reports
- Orencia: 9,671 reports
- Arava: 8,730 reports
All the drugs that are associated with Hair loss:
- Hair loss (3,775 drugs)
Common conditions associated with Hair loss:
- Rheumatoid arthritis: 18,564 reports
- Multiple sclerosis: 13,366 reports
- Breast cancer: 11,002 reports
- Chemotherapy: 8,910 reports
- High blood pressure: 5,484 reports
All the conditions that are associated with Hair loss:
- Hair loss (3,314 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on teriflunomide (the active ingredients of Aubagio) and Aubagio (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Linaclotide and Fluid Retention - now
- Solu-Medrol and Protamine Sulfate drug interaction - 2 seconds ago
- Alfuzosin Hydrochloride and Thrombocytopenia - 3 seconds ago
- How effective is Voltaren for Tendonitis? - 3 seconds ago
- Relenza and Iron Deficiency Anaemia - 9 seconds ago
- Multiple Sclerosis and Tonsillitis - 16 seconds ago
- Essential Tremor and Diplopia - 24 seconds ago
- How effective is Cymbalta for Peripheral Neuropathy? - 25 seconds ago
- How effective is Cymbalta for Neuropathy - Peripheral? - 25 seconds ago
- Fentanyl-100 and Diabetic Ketoacidosis - 25 seconds ago